Sinopharm Group Co. Ltd. — Earnings Release 2025

Aug 21, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

国药集团

SINOPHARM

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC

FOR THE SIX MONTHS ENDED 30 JUNE 2025

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 21 August 2025 (the "Announcement") issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the 2025 interim report of China National Medical Device Co., Ltd. (中國醫療器械有限公司)(“CNMDC”), a subsidiary of the Company.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the six months ended 30 June 2025 (the "Reporting Period") as set out in the Announcement.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

---

PRINCIPAL UNAUDITED FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS OF CNMDC

Unit: Yuan
Currency: RMB

	The Reporting Period	Same period of last year	Changes of this period over the same period of last year
Revenue	36,362,746,042.44	36,908,522,536.26	-1.48%
Operating profit	684,176,599.68	745,979,066.39	-8.28%
Total comprehensive income attributable to owners of the parent company	294,606,310.11	291,632,700.32	1.02%
Net cash flow arising from operating activities	-2,481,582,321.54	-7,726,076,201.83	-67.88%
	At the end of the Reporting Period	At the beginning of the Reporting Period	Changes of this period-end over the beginning of this period
Total assets	64,091,995,047.12	61,661,013,678.38	3.94%
Total equity attributable to owners of the parent company	8,088,149,575.48	7,884,395,529.18	2.58%

By order of the Board
Sinopharm Group Co. Ltd.
Zhao Bingxiang
Chairman

Shanghai, the PRC
21 August 2025

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Sun Jinglin; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.

2